What Instil Bio, Inc. does.

In January 2026 we announced our wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of our former lead product candidate, AXN-2510, a bispecific antibody targeting both programmed death-ligand 1 and the family of vascular endothelial growth factors in solid tumor cancers. Axion Bio in-licensed AXN-2510 from ImmuneOnco Biopharmaceuticals (Shanghai) Inc., or ImmuneOnco, in August 2024. The license and collaboration agreement with ImmuneOnco was terminated in January 2026. Prior to developing AXN-2510, our development efforts were focused on pursuing the development of cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for the treatment of cancer.

We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.

The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and a strong emphasis on intellectual property. We believe that our approach, strategy and experience provide us with certain competitive advantages. However, we expect substantial competition from many sources, including major pharmaceutical, specialty pharmaceutical, and existing or emerging biotechnology companies. Many of our potential competitors, either alone or through collaborations, have significantly greater financial resources and expertise in identifying acquisition and in-licensing opportunities, research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These entities also compete with us in recruiting and retaining qualified personnel and, assuming we in-license or acquire one or more new therapeutic product candidates, in establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring complementary or necessary technologies. As a result, potential competitors may discover, develop, license or commercialize products before or more successfully than we do.

Revenue and profit, by fiscal year.

More on TIL.

• Instil Bio, Inc. summary
• Instil Bio, Inc. financial statements
• Instil Bio, Inc. key metrics
• Instil Bio, Inc. health scores and style box
• Instil Bio, Inc. earnings
• Instil Bio, Inc. dividends
• Instil Bio, Inc. valuation
• Instil Bio, Inc. ownership and insiders
• Instil Bio, Inc. peers

Figures from Instil Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.